StockData

Viridian Therapeutics, Inc.\DE vs Zentalis Pharmaceuticals

VRDN and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VRDN and ZNTL compare

Viridian Therapeutics, Inc.\DE is the larger company, worth 32 times as much as Zentalis Pharmaceuticals ($3.4B against $107M).

Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVRDNZNTL
Size and price
Market cap$3.4B$107M
Share price$30.06$1.49
Change, 1 year4.5%12.0%
Change, 5 years64.3%−98.0%
Beta (5Y)−0.135.80
Employees252106
StockData Score
Total score46 (better)
Valuation score01 (better)
Growth score2 (better)0
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/S47.9×–
P/B5.1×0.7× (better)
FCF yield−9.8% (better)−120%
Fair value$8.47–
Margin of safety−255%–
Growth
Revenue growth (TTM)23220%–
Revenue growth, 5Y average132%–
Profitability
Operating margin−570%–
Net margin−544%–
FCF margin−471%–
Return on equity−65.7% (better)−66.7%
Financial health
Debt / equity–0.00
Interest coverage−26.0×–
Current ratio16.95 (better)4.82
Altman Z-score2.65 (better)−8.91
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield−1.7%–
Shareholder yield−1.7%0.00% (better)
Ownership
Held by institutions120%66.1%
Held by insiders21.8%58.0%
Insider net buying, 12 months$19.6M (better)$12.8M
Short interest, % of float19.2%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.